Transcode Therapeutics Stock

Transcode Therapeutics Debt/EBITDA

Total Debt to EBITDA Ratio of Transcode Therapeutics (RNAZ) as of Sep 15, 2026.

Debt/EBITDA

0.00

Last updated:

Total Debt to EBITDA Ratio of Transcode Therapeutics is 2026 0.00 . Total Debt to EBITDA Ratio of Transcode Therapeutics was 2025 0.00 . It decreases by % lower compared to the previous year.

The Transcode Therapeutics Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-1.14 USD
Jan 1, 2019
-2.03 USD
Jan 1, 2020
-2.87 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
The Transcode Therapeutics Debt/EBITDA history
YEARDebt/EBITDAYoY
0.00—
0.00—
0.00—
0.00-100.00%
-2.87+41.42%
-2.03+78.88%
-1.14—
Access this data via the Eulerpool API
Get Free API Key

Transcode Therapeutics Stock analysis

What does Transcode Therapeutics do? Transcode Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transcode Therapeutics stock

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Transcode Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Leverage — Transcode Therapeutics

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Transcode Therapeutics